A investigator-sponsored clinical trial assessing SC451
Latest Information Update: 15 May 2025
At a glance
- Drugs SC 451 (Primary)
 - Indications Type 1 diabetes mellitus
 - Focus Adverse reactions; First in man; Proof of concept
 
Most Recent Events
- 08 May 2025 According to Sana Biotechnology media release, the company expects to share additional data in 2025 and file an IND for SC451 as early as 2026.
 - 08 May 2023 According to Sana Biotechnology media release, the company expects initial data from this investigator-sponsored trial later this year.
 - 14 Apr 2023 New trial record